Ambirix Market (Prophylactic Hepatitis B Virus Vaccines) Analysis and 2022 Forecast adds report “Ambirix (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022” to its store.

Ambirix (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022


Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Request a sample copy of this report @ .

Ambirix [Hepatitis A (Inactivated) & Hepatitis B (rDNA) Vaccine] is GSK’s bivalent combination vaccine that protects children and adolescents against disease caused by HAV and acute and chronic infections caused by all known strains of HBV. Ambirix contains the antigenic components used in GSK’s Havrix (formalin-inactivated HAV) and GSK’s Engerix-B (yeast-derived recombinant HBsAg). In 2002, Ambirix was approved in the 5EU for active immunization of children and adolescents 1-15 years of age utilizing a two-dose regimen for primary vaccination.


- Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Ambirix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Ambirix for the UK from 2012 to 2022.
- Sales information covered for the UK.

Complete report is available @ .

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Ambirix performance
- Obtain sales forecast for Ambirix from 2012-2022 in the UK.

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12

Inquire for discount on this report @ .

3.1 Overview 12
3.2 Etiology and Pathophysiology 13
3.2.1 Etiology 13
3.2.2 Pathophysiology 16
3.3 Symptoms 18
3.4 Prognosis 20
4 Vaccination Recommendations and Coverage Rates 21
4.1 Overview 21
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 25
6 Ambirix 28
6.1 Overview 28
6.2 Immunogenicity 29
6.3 Safety 30
6.4 SWOT Analysis 31

Purchase a copy of this report @ .

Browse Hepatitis Drugs Industry Reports @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter :!/RnRMR

Facebook :

Google Plus :